375856-74-9

Upstream product

• 140-67-0 Estragole 
• 51410-45-8 estragole oxide 
• 20401-88-1 3-(4-methoxyphenyl)propional 

Downstream Products

• 375856-75-0 (R)-(-)-2-(4-methoxybenzyl)oxirane 
• 237736-11-7 (-)-(4S,5R)-5-hydroxymethyl-4-(4-methoxyphenyl)-1,3-oxazolidin-2-one 
• 220736-25-4 (4R,5R)-cytoxazone 
• 383420-35-7 (2R,3R)-3-tert-butoxycarbonylamino-3-(4-methoxyphenyl)-1,2-propanediol 
• 922728-69-6 sulfamic acid 2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-phenyl)-propyl ester 
• 922728-70-9 (4R,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-4-(4-methoxy-phenyl)-[1,2,3]oxathiazinane 2,2-dioxide 
• 922728-68-5 2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-phenyl)-propan-1-ol 
• 922728-71-0 (4R,5R)-4-(4-Methoxy-phenyl)-2,2-dioxo-2λ⁶-[1,2,3]oxathiazinan-5-ol 

Relevant academic research and scientific papers

Studies directed toward the synthesis of hedycoropyrans: total synthesis of des-hydroxy (?)-hedycoropyran B (ent-rhoiptelol B)

A full account of our efforts directed towards the synthesis of the diarylheptanoid-derived natural products hedycoropyrans that led to the total synthesis of ent-rhoiptelol B is described. In this endeavor, we have attempted two distinct synthetic strategies to access hedycoropyrans A and B, which led us to establish a facile synthetic route for des-hydroxy (?)-hedycoropyran B (ent-rhoiptelol B) from simple and readily accessible building blocks of 4-allylanisole and vanillin, employing Sharpless asymmetric epoxidation, CBS reduction, and an intramolecular AgOTf-catalyzed oxa-Michael reaction of suitably functionalized hydroxy-ynone as key transformations. The investigations disclosed herein will provide insights into designing novel synthetic routes for THP-DAH-derived natural products.

Organocatalytic approach to (s)-1-arylpropan-2-ols: Enantioselective synthesis of the key intermediate of antiepileptic agent (-)-talampanel

An efficient organocatalytic route for the preparation of enantioselective synthesis of (S)-1-arylpropan-2-ols derivatives, including the key intermediate of antiepileptic agent (-)-talampanel is described. The key steps involved are L-proline-catalyzed a

Enantioselective synthesis of (-)-cytoxazone and (+)-epi-cytoxazone via Rh-catalyzed diastereoselective oxidative C-H aminations

An efficient enantioselective synthesis of (-)-cytoxazone (1) and (+)-epi-cytoxazone (2) using proline-catalyzed asymmetric α-amino-oxylation of aldehydes followed by Rh-catalyzed diastereoselective oxidative C-H amination as the key steps is described. s

Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin- 4-ol: A novel NR1/2B subtype selective NMDA receptor antagonist

Starting from Ro-25-6981 as a lead compound, highly potent and selective NR1/2B subtype selective NMDA receptor antagonists, with low activity at α1 adrenergic receptors were developed.